$11.52
0.17% yesterday
NYSE, Sep 12, 10:04 pm CET
ISIN
US03969F1093
Symbol
RCUS

Arcus Biosciences Stock price

$11.52
+1.85 19.13% 1M
+1.82 18.76% 6M
-3.37 22.63% YTD
-5.87 33.76% 1Y
-14.25 55.30% 3Y
-11.47 49.89% 5Y
-5.48 32.24% 10Y
-5.48 32.24% 20Y
NYSE, Closing price Fri, Sep 12 2025
+0.02 0.17%

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$410.0m
Net debt
positive
Cash
$911.0m
Shares outstanding
106.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.7 | 5.2
EV/Sales
1.6 | 1.7
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
42.2%
Return on Equity
-58.4%
ROCE
-39.1%
ROIC
-529.9%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$262.0m | $236.5m
EBITDA
$-328.0m | $-474.6m
EBIT
$-338.0m | $-421.9m
Net Income
$-298.0m | $-409.0m
Free Cash Flow
$-342.0m
Growth (TTM | estimate)
Revenue
6.1% | -8.3%
EBITDA
-24.2% | -58.2%
EBIT
-23.8% | -36.1%
Net Income
-19.7% | -44.5%
Free Cash Flow
-28.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-125.2% | -200.7%
EBIT
-129.0%
Net
-113.7% | -173.0%
Free Cash Flow
-130.5%
More
EPS
$-2.8
FCF per Share
$-3.2
Short interest
14.1%
Employees
627
Rev per Employee
$410.0k
Show more

Is Arcus Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Arcus Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Arcus Biosciences forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a Arcus Biosciences forecast:

Buy
84%
Hold
16%

Financial data from Arcus Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
262 262
6% 6%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 115 115
5% 5%
44%
- Research and Development Expense 485 485
22% 22%
185%
-328 -328
24% 24%
-125%
- Depreciation and Amortization 10 10
11% 11%
4%
EBIT (Operating Income) EBIT -338 -338
24% 24%
-129%
Net Profit -298 -298
20% 20%
-114%

In millions USD.

Don't miss a Thing! We will send you all news about Arcus Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcus Biosciences Stock News

Neutral
Seeking Alpha
2 days ago
Arcus Biosciences, Inc. (NYSE:RCUS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Jennifer Jarrett - Chief Operating Officer Richard Markus - Chief Medical Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning.
Neutral
Business Wire
4 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 19,300 shares of the Company's comm...
Neutral
Seeking Alpha
9 days ago
Arcus Biosciences, Inc. (NYSE:RCUS ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Terry Rosen - Co-Founder, Chairman & CEO Jennifer Jarrett - Chief Operating Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst So welcome, everyone. I'm Yig...
More Arcus Biosciences News

Company Profile

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Head office United States
CEO Terry Rosen
Employees 627
Founded 2015
Website arcusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today